Clinical outcomes and cost minimization with an alternative dosing regimen for meropenem in a community hospital

Pharmacotherapy

Volumn 27, Issue 12 I, 2007, Pages 1637-1643

  Patel, Gita Wasan ^a   Duquaine, Susan M ^a   McKinnon, Peggy S ^b  

^a Medical Center of Plano   (United States)

^b BARNES JEWISH HOSPITAL   (United States)

Author keywords

Alternative dosing; Clinical outcomes; Cost minimization; Meropenem; Pharmacodynamics; Pharmacoeconomics

Indexed keywords

AMINOGLYCOSIDE; LINEZOLID; MEROPENEM; METRONIDAZOLE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; COST MINIMIZATION ANALYSIS; DEMOGRAPHY; DRUG COST; DRUG SENSITIVITY; FOOD AND DRUG ADMINISTRATION; HOSPITALIZATION; HUMAN; KIDNEY FAILURE; MINIMUM INHIBITORY CONCENTRATION; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; COHORT STUDIES; COSTS AND COST ANALYSIS; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; HOSPITALS, COMMUNITY; HUMANS; LOGISTIC MODELS; MIDDLE AGED; RETROSPECTIVE STUDIES; SEPSIS; THIENAMYCINS; TREATMENT OUTCOME;

EID: 36849029745     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.27.12.1637     Document Type: Article

References (8)

1. Grant E, Nicolau DP, Nightingale CH, et al. Continuous infusion of beta-lactam antibiotics. Conn Med 1999;63(5):275-7.
2. Craig WA, Ebert SC. Continuous infusion of beta-lactam antibiotics. Antimicrob Agents Chemother 1992;31:139-43.
3. Drusano GL. Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin Infect Dis 2003;36(suppl 1):S42-50.
4. Kuti JI, Maglio D, Nightingale CH, et al. Economic benefit of a meropenem dosage strategy based on pharmacodynamic concepts. Am J Health Syst Pharm 2003;60:565-8.
5. Kotapati S, Nicolau DP, Nightingale CH. Clinical and economic benefits of a meropenem dosage strategy based on pharmacodynamic concepts. Am J Health Syst Pharm 2004;61:1264-70.
6. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
7. McGregor JC, Kim PW, Perencevich EN, et al. Utility of the chronic disease score and Charlson comorbidity index as comorbidity measures for use in epidemiologic studies of antibiotic-resistant organisms. Am J Epidemiol 2005;161:483-93.
8. Dellinger RP, Carlet JM, Masur H, et al. Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004;32:858-73. (Errata in Crit Care Med 2004;32(6):1448 and 2004;32(10):2169-70.)